Joanne Brodfuehrer

Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

Peter L. Toogood, Patricia J. Harvey, Joseph T. Repine et al. · Journal of Medicinal Chemistry · 2005 · 498 citations · Full text

Drug Target, Exquisite Selectivity, Pharmacotherapy +19

Discovery of Clinical Candidate 1-{[(2 <i>S</i> ,3 <i>S</i> ,4 <i>S</i> )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Katherine L. Lee, Catherine M. Ambler, David R. Anderson et al. · Journal of Medicinal Chemistry · 2017 · 138 citations · Full text

Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans

Susan Hurst, Cho‐Ming Loi, Joanne Brodfuehrer et al. · Expert Opinion on Drug Metabolism & Toxicology · 2007 · 117 citations

Drug Oral Bioavailability, Therapeutic Response, Pharmacokinetics +16

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial

Aaron Winkler, Weiyong Sun, Saurav De et al. · Arthritis & Rheumatology · 2021 · 86 citations · Full text

Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery

Chad Stoner, Adriaan Cleton, Kjell Johnson et al. · International Journal of Pharmaceutics · 2003 · 61 citations

Pharmaceutical Research, Preclinical Drug Evaluation, Oral Bioavailability Projection +10